期刊文献+

米非司酮阴道环的处方前研究 被引量:1

Pre-formulation study on mifepristone-loaded vaginal ring
原文传递
导出
摘要 目的:对米非司酮进行处方前研究,为设计优良的缓释米非司酮阴道环的处方提供依据。方法:采用紫外-可见分光光度法测定米非司酮在水和磷酸盐缓冲液(pH4.0和pH6.8)介质中的溶解度;以差式扫描量热法(DSC)对米非司酮在硅橡胶中的溶解度进行测定;以PVPK30为载体,制备米非司酮固体分散体,并测定其在pH4.0磷酸盐缓冲液中的溶解度;分别考察了含有米非司酮、米非司酮与辅料PVPK30物理混合物及固体分散体的阴道环的体外释放度,以及米非司酮与辅料PVPK30和载体硅橡胶之间的相容性。结果:米非司酮在水和磷酸盐缓冲液介质中于24 h内稳定性良好,在pH4.0磷酸盐缓冲液中的溶解度最大,而米非司酮固体分散体在pH4.0磷酸盐缓冲液中的溶解度则显著增加;米非司酮在硅橡胶中的溶解度为16.80 mg·g-1;载有米非司酮原料药和物理混合物的阴道环无法释放出药物,而含有米非司酮固体分散体的阴道环则能很好地释放药物;米非司酮与辅料PVPK30和硅橡胶的混合物在光照、高温及高湿条件下有关物质未见显著增加。结论:处方前研究表明米非司酮适合制备成阴道黏膜给药系统,固体分散技术是制备米非司酮阴道环的关键技术,它能够使难溶性药物从载体硅橡胶中释放出来。米非司酮与辅料PVPK30和载体硅橡胶之间的相容性良好。 OBJECTIVE To study the properties of mifepristone for designing the optimal vaginal ring containing mifepris- tone. METHODS The saturation concentrations of mifepristone in water and phosphate buffer (pH 4. 0 and pH 6. 8) were in- vestigated by UV visible spectrophotometric method. The solubility of mifepristone in silicone elastomer was determined by dif- ferential scanning calorimeter. The solid dispersion (SD) was prepared with PVPK30 as the carrier,and the solubility of SD of mifepristone in pH 4. 0 phosphate buffer was determined. The drug release in vitro characteristics of vaginal rings containing free mifepristone, physical mixture and solid dispersion of mifepristone with PVPK30 were compared. The eompatibilities of mifepristone with PVPK30 or silicon elastomer were evaluated. RESULTS Mifepristone had a good solubility in pH 4. 0 phos- phate buffer and stability in water and phosphate buffer within 24 h, and the solubility of solid dispersion of mifepristone was found to be significantly increased than that of mifepristone in pH 4. 0 phosphate buffer. The solubility of mifepristone in sili- cone elastomer was 16. 80 mg.g 1. Mifepristone could only be released from the vaginal rings loading solid dispersion of mile pristone with PVPK30. There was no significant change on the related substance of mifepristone with PVPK30 or silicon elas tomer under light radiation, high temperature and high humidity. CONCLUSION The vaginal drug delivery system is suitable for the delivery of mifeprisotne. The solid dispersion technology is an important factor to ensure mifepristone release from drug- loaded vaginal ring. Finally mifepristone has a good capacitability with PVPK30 and silicon elastomer, there are no obvious in-teractions between them.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2013年第24期2015-2018,共4页 Chinese Journal of Hospital Pharmacy
基金 十二五国家科技支撑计划课题项目(编号:2012BAI31B00)
关键词 米非司酮 阴道环 处方前研究 mifepristone vaginal ring pre-formulation
  • 相关文献

参考文献14

  • 1Agarwal M, Das V, Agarwal A, etal. Evaluation of mifepris tone as a once a month contraceptive pill [J]. Am J Obstet Gy- neeol., 29, 2001(5) : e27-e29.
  • 2Feng C, Meldrum S, Fiscella K. Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristone [J]. Int J Gynecol Obstet, 2010, 109(2): 121- 124.
  • 3Bagaria M, Suneja A, Vaid N B, etal. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial [J]. Aust N Z J Obstet Gynae- col, 2009, 49(1): 77- 83.
  • 4Engman M, Granberg S, Williams A R, et al. Mifepristonefor treatment of uterine leiomyoma. A prospective randomized placebo controlled trial [J]. Hum Reprod, 201)9, 24 (8): 1870-1879.
  • 5董瑞谦,滕艳妮,俆延华,郭瑞臣.不同厂家米非司酮片的人体药动学比较[J].中国医院药学杂志,2012,32(21):1716-1719. 被引量:5
  • 6Quereux C, Raimond E, Graesslin O. Oral contraceptives and non-oral contraceptives: realities [J]. J Fynecol Obstet Biol Reprod (Paris), 2009, 5(38):69-83.
  • 7段雪艳,陈凯,王介东,宁美英.载药阴道环的研究进展[J].中国药学杂志,2012,47(11):841-846. 被引量:9
  • 8张莹,李春晓,段雪艳,刘颖,宁美英.包膜型PVP_K30屈螺酮固体分散体阴道环相关研究[J].中国医院药学杂志,2013,33(7):507-510. 被引量:3
  • 9周菊贤,刘晓瑷.新型非口服激素避孕方式的研究进展[J].国际生殖健康与计划生育杂志,2009,28(4):245-248.
  • 10中国药典.二部[S].2010:凡例ⅩⅦ.

二级参考文献13

  • 1庞雪冰,梅海燕,左明达,熊忠明,吴熙瑞.米非司酮胶囊的相对生物利用度[J].中国医院药学杂志,2005,25(2):113-115. 被引量:7
  • 2杨艳青,程弘夏,刘俊勇,黄凤英,裴丽,朱长虹.高效液相色谱法测定米非司酮胶囊相对生物利用度[J].中国医院药学杂志,2006,26(9):1072-1074. 被引量:6
  • 3周菊贤,刘晓瑷.新型非口服激素避孕方式的研究进展[J].国际生殖健康与计划生育杂志,2009,28(4):245-248.
  • 4Fine PM, Tryqqestad J, Meyers NJ, et al. Safety and accept- ability with the use of a contraceptive vaginal ring after surgi cal or medical abortion[J]. Contraception, 20117, 5(75): 367- 371.
  • 5国家食品药品监督管理局.中药、天然药物制剂研究技术指导原则[M].2003.
  • 6魏树礼,李凡.漫反射光谱法和线性变温法和线性变温法在研究抗坏血酸稳定性中的应用[J].医药工业,1983,7:13-16.
  • 7Signore EC, Dellutri A, Salvo AD, et al. Compatibility study between cherbulerol and tablet excipients using defferent scan- ning calorimetry[J]. Drug Dev Ind Pharm, 1986, 12(4) : 603- 620.
  • 8Botha SA, Loller AP. Compatibility study between ketoprofen and tablet excipients using different scanning calorimetry[J]. Drug Dev Ind Pharm, 1989,15 (3) : 415-426.
  • 9United States Pharmacopoeia[S]. 32-NF27. 2011. 2220.
  • 10周静,雷贞武.新型短效复方口服避孕药——屈螺酮炔雌醇片[J].中国计划生育学杂志,2009,17(6):371-373. 被引量:24

共引文献175

同被引文献3

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部